Abstract
In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was
| Original language | English |
|---|---|
| Pages (from-to) | 1400-1406 |
| Number of pages | 7 |
| Journal | Hypertension |
| Volume | 60 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2012 |
Fingerprint
Keywords
- ambulatory blood pressure
- angiotensin receptor blockers
- angiotensin-converting enzyme inhibitors
- antihypertensive treatment
- high cardiovascular risk
ASJC Scopus subject areas
- Internal Medicine
Cite this
Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). / Mancia, Giuseppe; Parati, Gianfranco; Bilo, Grzegorz; Gao, Peggy; Fagard, Robert; Redon, Josep; Czuriga, Istvan; Polák, Martin; Ribeiro, Josè M.; Sanchez, Ramiro; Trimarco, Bruno; Verdecchia, Paolo; Van Mieghem, Walter; Teo, Koon; Sleight, Peter; Yusuf, Salim.
In: Hypertension, Vol. 60, No. 6, 12.2012, p. 1400-1406.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ambulatory blood pressure values in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET)
AU - Mancia, Giuseppe
AU - Parati, Gianfranco
AU - Bilo, Grzegorz
AU - Gao, Peggy
AU - Fagard, Robert
AU - Redon, Josep
AU - Czuriga, Istvan
AU - Polák, Martin
AU - Ribeiro, Josè M.
AU - Sanchez, Ramiro
AU - Trimarco, Bruno
AU - Verdecchia, Paolo
AU - Van Mieghem, Walter
AU - Teo, Koon
AU - Sleight, Peter
AU - Yusuf, Salim
PY - 2012/12
Y1 - 2012/12
N2 - In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was
AB - In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was
KW - ambulatory blood pressure
KW - angiotensin receptor blockers
KW - angiotensin-converting enzyme inhibitors
KW - antihypertensive treatment
KW - high cardiovascular risk
UR - http://www.scopus.com/inward/record.url?scp=84870241880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870241880&partnerID=8YFLogxK
U2 - 10.1161/HYPERTENSIONAHA.112.199562
DO - 10.1161/HYPERTENSIONAHA.112.199562
M3 - Article
C2 - 23071122
AN - SCOPUS:84870241880
VL - 60
SP - 1400
EP - 1406
JO - Hypertension
JF - Hypertension
SN - 0194-911X
IS - 6
ER -